Spruce Biosciences (SPRB) Change in Account Payables (2022 - 2026)
Spruce Biosciences (SPRB) posted quarterly Change in Account Payables of $1.7 million for Q1 2026, up 191.1% year-over-year from $584000.0 in Q1 2025, and up 483.75% quarter-over-quarter from -$443000.0 in Q4 2025.
Spruce Biosciences (SPRB) Change in Account Payables (2022 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Change in Account Payables for 5 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 191.1% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $764000.0 (up 6466.67% YoY), while the FY2025 annual figure was -$352000.0, up 82.72% from the prior year.
- Change in Account Payables grew to $1.7 million in Q1 2026 per SPRB's latest filing, from -$443000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.2 million in Q3 2023 and bottomed at -$2.5 million in Q2 2023.
- Historically, Change in Account Payables has averaged -$10588.2 across 5 years, with a median of $180000.0 in 2023.
- On a YoY basis, Change in Account Payables climbed as much as 217.97% in 2023 and fell as far as 844.94% in 2023.
- Spruce Biosciences' Change in Account Payables stood at -$755000.0 in 2022, then soared by 123.84% to $180000.0 in 2023, then plunged by 380.0% to -$504000.0 in 2024, then gained by 12.1% to -$443000.0 in 2025, then soared by 483.75% to $1.7 million in 2026.
- Business Quant data shows SPRB's Change in Account Payables at $1.7 million in Q1 2026, -$443000.0 in Q4 2025, and $579000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.43 Mn |
| Jun 30, 2026 | -1.43 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | -443,000.00 |
| Dec 31, 2025 | -443,000.00 |
| Sep 30, 2025 | 579,000.00 |
| Sep 30, 2025 | 579,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 584,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Dec 31, 2024 | -504,000.00 |
| Dec 31, 2024 | -504,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | -1.21 Mn |
| Jun 30, 2024 | -1.21 Mn |
| Mar 31, 2024 | -1.44 Mn |
| Mar 31, 2024 | -1.44 Mn |